Status:

UNKNOWN

Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI

Lead Sponsor:

University of Novi Sad

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Conditions:

HIV I Infection

HIV Associated Lipodystrophy

Eligibility:

MALE

18-45 years

Phase:

NA

Brief Summary

Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio...

Detailed Description

Serbia is low income country with epidemiology of HIV infection resembling those in developed countries, with average age of patients around 50 years and majority of them being the MSM population. Ano...

Eligibility Criteria

Inclusion

  • Male (in order to eliminate the hormonal influences on the levels of brain metabolites),
  • older than 18 years,
  • HIV seropositivity confirmed on PCR testing,
  • undetectable viral load for over one year,
  • conventional magnetic resonance imaging (MRI) normal.
  • In group I, the additional criterion would be stable cART not containing INSTI for over one year.
  • In group II, the inclusion criteria will be the INSTI base regimen introduced at least one year prior to imaging.

Exclusion

  • active infiltrative or infective/opportunistic neurological illness,
  • chronic neurological diseases (multiple sclerosis, vascular and non-vascular dementia, other neurodegenerative conditions),
  • active abuse of narcotic drugs,
  • hepatitis B or C coinfection,
  • deep white matter lesions (focal or diffuse, such as lacunar stroke, leukoaraiosis, infiltrative or infective foci, metastases etc.),
  • International HIV Dementia Scale (IHDS) score \<10 (only neuro-asymptomatic subjects would be included in the study), and
  • contraindications for MRI examination

Key Trial Info

Start Date :

May 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2022

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT04887675

Start Date

May 1 2021

End Date

October 1 2022

Last Update

December 1 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Medicine, University of Novi Sad

Novi Sad, Serbia, 21000

Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI | DecenTrialz